Explore the latest treatment strategies and emerging trends in metabolic dysfunction–associated steatohepatitis (MASH) with expert insights from Dr. Nadege Gunn. This video covers current FDA-approved therapies for patients with moderate to advanced fibrosis, including Resmetirom (Rezdiffra) and Semaglutide, and explains how lifestyle interventions remain the foundation of care. Learn how to personalize treatment decisions based on patient comorbidities such as obesity and type 2 diabetes, when to initiate GLP-1 therapy versus resmetirom, and how these therapies can be used together in real-world practice. The discussion also highlights current gaps in treatment for early-stage disease and cirrhosis, while offering a forward-looking perspective on combination therapy and the next generation of antifibrotic agents in development. Designed for hepatology and gastroenterology clinicians, this video provides practical, up-to-date guidance to help optimize outcomes for patients with MASH.